Compare Newmont Corporation (NEM) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Novavax Inc — how do they compare? Newmont Corporation trades at $117.8 (market cap $121.75B), while Novavax Inc trades at $12.79 (market cap $1.82B). The key difference: Newmont Corporation is far larger — about 66.9× Novavax Inc's market cap, and Newmont Corporation pays a 0.9% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and Novavax Inc for 59 Days on average.
| NEM | NVAX | |
|---|---|---|
Market Cap | $121.75B | $1.82B |
Volume | 5,421,125 | 6,198,505 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $12.56 |
52-Week Low | $78.63 | $6.22 |
Typical Hold Time | 58 Days | 59 Days |
Enterprise Value | $118.34B | $1.39B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $117.84, up 3.79% over the past 24 hours, with a bearish technical signal but strong fundamental performance. The company reported record free cash flow of $5.3 billion in H1 2026 and has consistently beaten earnings estimates in recent quarters. Revenue grew to $22.67 billion in 2025, with net income reaching $7.09 billion, reflecting a robust profit margin of 31.25%.
The outlook remains positive due to strong cash flow generation and operational improvements, though near-term technical weakness and gold price volatility present risks. Analyst consensus is strongly bullish with a $136.83 price target, indicating potential upside. Key risks include dependence on gold prices and execution of growth projects.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
